Scholarlink

<p>Organoids are three-dimensional (3D) culture models derived from patient tumor samples that replicate the structure, function, and genetic characteristics of their source tissues. These models hold significant promise for transforming oncology by providing a&#xa0;robust platform upon which to test therapeutic responses and enabling personalized treatment strategies. Patient-derived organoids (PDOs) preserve tumor heterogeneity and have demonstrated predictive potential for therapeutic responses in various cancers, including colorectal, pancreatic, and breast cancer. Recent advancements, such as the incorporation of components of the tumor microenvironment and extracellular matrix as well as the development of microfluidic organ-on-chip systems, are further enhancing their physiological relevance of these models. While challenges persist, particularly in standardization and scalability. these are actively being addressed through national multicenter initiatives like the Organoid Platform of the German Cancer Consortium (DKTK). Despite these hurdles, PDOs have already shown substantial promise in predictive and prognostic applications. This review examines the current role of PDOs in oncology, their integration with innovative technologies, and future directions for advancing cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Organoide als prädiktive Modelle in der Onkologie

  • 期刊论文

  • 发表日期：

    2025年1月27日

查看全文
  • Maximilian Reichert,
  • Daniel E. Stange,
  • Henner F. Farin

摘要

Organoids are three-dimensional (3D) culture models derived from patient tumor samples that replicate the structure, function, and genetic characteristics of their source tissues. These models hold significant promise for transforming oncology by providing a robust platform upon which to test therapeutic responses and enabling personalized treatment strategies. Patient-derived organoids (PDOs) preserve tumor heterogeneity and have demonstrated predictive potential for therapeutic responses in various cancers, including colorectal, pancreatic, and breast cancer. Recent advancements, such as the incorporation of components of the tumor microenvironment and extracellular matrix as well as the development of microfluidic organ-on-chip systems, are further enhancing their physiological relevance of these models. While challenges persist, particularly in standardization and scalability. these are actively being addressed through national multicenter initiatives like the Organoid Platform of the German Cancer Consortium (DKTK). Despite these hurdles, PDOs have already shown substantial promise in predictive and prognostic applications. This review examines the current role of PDOs in oncology, their integration with innovative technologies, and future directions for advancing cancer treatment.